Article
Mechanistic target of rapamycin (mTOR) regulates self-sustained quiescence, tumor…
medRxiv · 2022 · Carole Nicco
Key facts
| Title | Mechanistic target of rapamycin (mTOR) regulates self-sustained quiescence, tumor indolence and late clinical metastasis in a Beclin-1-dependent manner. |
|---|---|
| First author | Carole Nicco |
| Journal | medRxiv |
| Published | Aug 25, 2022 |
| DOI | 10.1101/2022.05.05.490726 |
| Devices mentioned | 217566, DEN000008, K002288, K012371, K022086, K033734, K103302, K133972, K142003, K170858, K191495, K192440 and 4 more |
| Product codes mentioned | CBI, CFN, DDG, DHB, IZH, IZL, JJF, MQB, MUE, NDS, OWB, DEW and 8 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1